Pharmacotherapies in the Management of Obsessive—Compulsive Disorder

  title={Pharmacotherapies in the Management of Obsessive—Compulsive Disorder},
  author={Pierre U. Blier and Rami Habib and Martine Flament},
  journal={The Canadian Journal of Psychiatry},
  pages={417 - 430}
Few medications are effective in treating obsessive–compulsive disorder (OCD). As monotherapy, only potent serotonin (5-HT) reuptake inhibitors (SRIs) consistently exert an intrinsic therapeutic action in OCD. Their use in OCD, however, differs from their use in depression. This paper first reviews the evidence supporting the key role of 5-HT as a pivotal neurotransmitter in the anti-OCD response. Then, we describe the practicalities of SRI use, followed by the steps that can be taken when… 

Figures and Tables from this paper

Addition of trazodone to sertraline: a probable synergistic action in a case of obsessive-compulsive disorder.
Preliminary evidence supports the addition of antipsychotics to SRIs in obsessive-compulsive disorder (OCD), which combine serotonin-dopamine antagonism with the advantage of being well tolerated, including a low potential for inducing motor side-effects.
D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder
The present results fail to support the use of D-cycloserine with exposure and response prevention therapy for adult obsessive–compulsive disorder and are the first to explore this question.
High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission.
In the following, a case is reported whereby pregabalin (PGB) added to QTP resulted in an impressive submergence of manic symptoms, and adjunctive medications with antimanic efficacy, but devoid of this side effect should clearly be recommendable.
Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study
The notions that oxytocin is involved in OCD pathophysiology, and that the anti-obsessive effects of SRIs are partly exerted through Oxytocinergic mechanisms, are supported.
Obsessive control and challenging tests. Experimental studies on neurobiological mechanisms in the pathogenesis and treatment of obsessive-compulsive disorder
DCS has been proven to possess the capability to enhance or accelerate the extinction of conditioned fear in Pavlonian fear paradigms and the hypothesis that disturbances in cognitive inhibition might lead to an increase of intrusive thoughts coming into consciousness, which may cause a more deliberately suppression of these thoughts, with a counterproductive effect.
D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis
D-cycloserine augmentation may enhance the efficacy of ERP therapy in reducing the symptomatic severity of OCD patients, especially at early stage of the treatment; therefore, DCS augmentation could possibly reduce treatment cost, reduce treatment drop and refusal rate, and help to improve access to the limited number of experienced therapists.
Obsessive-Compulsive Disorder
Improved understanding of OCD by clinicians is imperative to reduce the gap between symptom onset and eventual diagnosis and to promote early implementation of strategies for long-term symptomatic relief.


The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder.
The authors examine the role of the serotonergic system in the modulation or genesis of obsessive compulsive disorder and the potential for the use of the new serotonin (5-HT) reuptake inhibitors in
Evidence-based pharmacotherapy of obsessive-compulsive disorder.
  • N. Fineberg, T. Gale
  • Psychology, Medicine
    The international journal of neuropsychopharmacology
  • 2005
Key questions related to OCD pharmacotherapy are reviewed, synthesizing evidence derived from randomized controlled trials, meta-analyses and consensus guidelines, and SSRIs are the preferred option for long-term treatment in most cases.
Sequential administration of augmentation strategies in treatment‐resistant obsessive‐compulsive disorder: preliminary findings
Addition of the 5-HT1A/β-adrcnergic antagonist pindolol did not alter OCD symptomatology but produced a rapid improvement of depressive symptoms, and Tryptophan was added to the SRI pINDolol regimen, producing a significant improvement after 4 weeks, with further amelioration after 6 weeks.
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Adjunctive risperidone improved obsessions and depressed mood and was well tolerated in patients with SRI-refractory OCD.
WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults
Psychotherapy and pharmacotherapy for a minimum of 1–2 years is recommended before very gradual withdrawal may be considered, and available treatment guidelines recommend first-line use of an SSR1 in preference to clomipramine, due to the latter's less favorable adverse-event profile.
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Preliminary evidence is provided that adding olanzapine to SRIs is potentially efficacious and well tolerated in the short-term treatment of patients with refractory OCD.
Meta‐analysis of pharmacotherapy trials for obsessive‐compulsive disorder
This study supports previous work suggesting that increased serotonergic specificity is not necessarily correlated with greater efficacy in the treatment of OCD, and suggests that serotonin reuptake inhibitor (SRI) type had a significant effect on medication effect size.
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Data suggest that clomipramine's possibly superior efficacy in the treatment of obsessive-compulsive symptoms may not stem from its capacity to inhibit reuptake of norepinephrine.